Context Therapeutics stockholders approve increase in authorized common shares to 300M

Context Therapeutics Inc.

Authorized common shares increased from 200M to 300M via Certificate of Amendment filed June 24, 2026.
All seven director nominees elected with >63M votes for each; no dissident candidates.
Ratification of CohnReznick LLP as independent auditor for FY2026 approved with 72.76M votes.
91.88M shares outstanding; 79.27% quorum at annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.